← Back to Search

Immunotherapy Combination

Immunotherapy Combinations for Non-Small Cell Lung Cancer (Morpheus Lung Trial)

Phase 1 & 2
Recruiting
Research Sponsored by Hoffmann-La Roche
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate hematologic and end-organ function
Histologically or cytologically confirmed metastatic, non-squamous or squamous Non-Small Cell Lung Cancer (NSCLC)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through the end of the study (approximately 8 years)
Awards & highlights

Morpheus Lung Trial Summary

This trial will study whether immunotherapy-based treatment combinations can help patients with metastatic NSCLC. Two groups of patients will be enrolled, depending on whether they have received systemic therapy before. Treatment will be assigned based on eligibility.

Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer. Cohort 1 includes those who haven't had systemic therapy and have high PD-L1 in tumors. Cohort 2 has patients whose disease progressed after platinum-based and PD-L1/PD-1 inhibitor treatments. Participants must be able to perform daily activities with minimal assistance, have a life expectancy of at least 3 months, measurable disease, proper organ function, and agree to use contraception.Check my eligibility
What is being tested?
The study tests various immunotherapy combinations on two groups: one untreated for metastatic NSCLC (high tumor PD-L1 expression), the other previously treated but progressed. It assesses effectiveness, safety, and drug behavior in the body over two stages—initial treatment followed by an alternative if needed due to progression or side effects.See study design
What are the potential side effects?
Potential side effects include immune-related reactions affecting organs, infusion responses similar to allergic reactions, fatigue, gastrointestinal issues like nausea or diarrhea, blood abnormalities that can affect clotting or immunity levels increasing infection risk.

Morpheus Lung Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My blood and organs are functioning well.
Select...
My lung cancer is confirmed to be non-small cell type and has spread.
Select...
I have at least one tumor that can be measured.
Select...
My tumor can be easily reached for a biopsy.
Select...
I agree to either not have sex or use birth control, and not donate sperm while on treatment.
Select...
I have not received any systemic therapy for my metastatic NSCLC.
Select...
My tumor shows high PD-L1 levels, with a score of 50% or more.
Select...
My lung cancer has worsened despite treatment.
Select...
I am fully active or can carry out light work.

Morpheus Lung Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through the end of the study (approximately 8 years)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through the end of the study (approximately 8 years) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants with Objective Response
Secondary outcome measures
Disease Control
Duration of Response
Overall Survival After Randomization
+3 more

Morpheus Lung Trial Design

23Treatment groups
Experimental Treatment
Active Control
Group I: Stage 2: Cohort 2: Atezolizumab + RO6958688Experimental Treatment3 Interventions
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group II: Stage 2: Cohort 2: Atezolizumab + LinagliptinExperimental Treatment2 Interventions
Participants in the Atezolizumab + Linagliptin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group III: Stage 2: Cohort 2: Atezolizumab + DocetaxelExperimental Treatment2 Interventions
Participants in the Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who have received treatment with Atezolizumab + Docetaxel in Stage 1 will not receive this treatment in Stage 2.
Group IV: Stage 2: Cohort 1: Atezolizumab + Pemetrexed + CarboplatinExperimental Treatment3 Interventions
Participants in the Atezolizumab + Pemetrexed + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group V: Stage 2: Cohort 1: Atezolizumab + Gemcitabine + CarboplatinExperimental Treatment3 Interventions
Participants in the Atezolizumab + Gemcitabine + Carboplatin arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group VI: Stage 1: Cohort 2: Atezolizumab + Sacituzumab GovitecanExperimental Treatment2 Interventions
Participants in the Atezolizumab + Sacituzumab Govitecan arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group VII: Stage 1: Cohort 2: Atezolizumab + RO6958688Experimental Treatment3 Interventions
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group VIII: Stage 1: Cohort 2: Atezolizumab + IpatasertibExperimental Treatment2 Interventions
Participants in the Atezolizumab + Ipatasertib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group IX: Stage 1: Cohort 2: Atezolizumab + EvolocumabExperimental Treatment2 Interventions
Participants in the Atezolizumab + Evolocumab arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit.
Group X: Stage 1: Cohort 2: Atezolizumab + DocetaxelExperimental Treatment2 Interventions
Participants in Atezolizumab + Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XI: Stage 1: Cohort 2: Atezolizumab + CobimetinibExperimental Treatment2 Interventions
Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin, Atezolizumab + Gemcitabine + Carboplatin, Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XII: Stage 1: Cohort 2: Atezolizumab + CamonsertibExperimental Treatment2 Interventions
Participants in the Atezolizumab + Camonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XIII: Stage 1: Cohort 2: Atezolizumab + CPI-444Experimental Treatment2 Interventions
Participants in the Atezolizumab + CPI-444 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XIV: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + TiragolumabExperimental Treatment3 Interventions
Participants in the Atezolizumab + Bevacizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XV: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + RadiotherapyExperimental Treatment3 Interventions
Participants in the Atezolizumab + Bevacizumab + Radioatherapy arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XVI: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + CamonsertibExperimental Treatment3 Interventions
Participants in the Atezolizumab + Bevacizumab + Comonsertib arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XVII: Stage 1: Cohort 2: Atezolizumab + BevacizumabExperimental Treatment2 Interventions
Participants in Atezolizumab + Bevacizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XVIII: Stage 1: Cohort 1: Atezolizumab + Tiragolumab + XL092 (Zanzalintinib)Experimental Treatment3 Interventions
Participants in the Atezolizumab + Tiragolumab + XL092 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XIX: Stage 1: Cohort 1: Atezolizumab + RO6958688Experimental Treatment3 Interventions
Participants in the Atezolizumab + RO6958688 arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria. Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + Docetaxel treatment or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XX: Stage 1: Cohort 1: Atezolizumab + CobimetinibExperimental Treatment2 Interventions
Participants in the Atezolizumab + Cobimetinib arm will receive treatment (cycle length 28 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on 1L treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria. Participants who progressed on 2L/3L treatment, may have the option of receiving Atezolizumab + RO6958688, Atezolizumab + Docetaxel or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XXI: Stage 1: Cohort 2: DocetaxelActive Control1 Intervention
Participants in the Docetaxel arm will receive treatment (cycle length 21 days) until unacceptable toxicity or disease progression. Participants who progressed on treatment may have the option of receiving Atezolizumab + RO6958688 or Atezolizumab + Linagliptin treatment, provided they meet the eligibility criteria.
Group XXII: Stage 1: Cohort 1: Atezolizumab + TiragolumabActive Control2 Interventions
Participants in the Atezolizumab + Tiragolumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit.
Group XXIII: Stage 1: Cohort 1: AtezolizumabActive Control1 Intervention
Participants in the Atezolizumab arm will receive treatment (cycle length 21 days) until unacceptable toxicity or loss of clinical benefit. Participants who progressed on treatment, may have the option of receiving Atezolizumab + Pemetrexed + Carboplatin or Atezolizumab + Gemcitabine + Carboplatin treatment, provided they meet the eligibility criteria.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tocilizumab
2012
Completed Phase 4
~1840
Ipatasertib
2019
Completed Phase 3
~2340
Tiragolumab
2020
Completed Phase 2
~350
RO6958688
2016
Completed Phase 1
~380
Gemcitabine
2017
Completed Phase 3
~2070
Cobimetinib
2015
Completed Phase 3
~2630
Atezolizumab
2016
Completed Phase 3
~6040
Bevacizumab
2013
Completed Phase 4
~5280
Evolocumab
2011
Completed Phase 4
~13010
Docetaxel
1995
Completed Phase 4
~5620
Pemetrexed
2014
Completed Phase 3
~5250
Carboplatin
2014
Completed Phase 3
~6670
Linagliptin
2010
Completed Phase 4
~19930

Find a Location

Who is running the clinical trial?

Hoffmann-La RocheLead Sponsor
2,427 Previous Clinical Trials
1,088,476 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,198 Previous Clinical Trials
887,904 Total Patients Enrolled

Media Library

Atezolizumab (Immunotherapy Combination) Clinical Trial Eligibility Overview. Trial Name: NCT03337698 — Phase 1 & 2
Non-Small Cell Lung Cancer Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT03337698 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Camonsertib, Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Tiragolumab, Stage 1: Cohort 1: Atezolizumab + Cobimetinib, Stage 1: Cohort 1: Atezolizumab + RO6958688, Stage 1: Cohort 2: Docetaxel, Stage 1: Cohort 2: Atezolizumab + RO6958688, Stage 2: Cohort 1: Atezolizumab + Pemetrexed + Carboplatin, Stage 2: Cohort 2: Atezolizumab + RO6958688, Stage 2: Cohort 2: Atezolizumab + Docetaxel, Stage 1: Cohort 2: Atezolizumab + Bevacizumab + Radiotherapy, Stage 1: Cohort 1: Atezolizumab + Tiragolumab, Stage 1: Cohort 1: Atezolizumab + Tiragolumab + XL092 (Zanzalintinib), Stage 1: Cohort 2: Atezolizumab + Camonsertib, Stage 1: Cohort 2: Atezolizumab + Cobimetinib, Stage 1: Cohort 1: Atezolizumab, Stage 1: Cohort 2: Atezolizumab + Bevacizumab, Stage 2: Cohort 1: Atezolizumab + Gemcitabine + Carboplatin, Stage 1: Cohort 2: Atezolizumab + Ipatasertib, Stage 2: Cohort 2: Atezolizumab + Linagliptin, Stage 1: Cohort 2: Atezolizumab + CPI-444, Stage 1: Cohort 2: Atezolizumab + Evolocumab, Stage 1: Cohort 2: Atezolizumab + Docetaxel, Stage 1: Cohort 2: Atezolizumab + Sacituzumab Govitecan
Atezolizumab (Immunotherapy Combination) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03337698 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are engaged in the current clinical trial?

"This medical trial, sponsored by Hoffmann-La Roche, requires 435 participants who meet the inclusion criteria. Recruiting efforts will be centered around University Hospitals Case Medical Center, Seidman Cancer Center in Cleveland and Sarah Cannon Research Institute of Nashville."

Answered by AI

Has there been precedent for the utilization of RO6958688 in any other research?

"Presently, 1974 trials are being conducted with RO6958688 as the focus. Out of those studies 537 have reached Phase 3 and 99928 sites globally are hosting these investigations. Notably, St Leonards in New South Wales is a major centre for this medication's research."

Answered by AI

Can you provide an estimate of the amount of healthcare facilities presently hosting this experiment in the city?

"The trial is currently open for enrollment at University Hospitals Case Medical Center, Seidman Cancer Center in Cleveland, Ohio, Sarah Cannon Research Institute in Nashville, Tennessee and Christiana Care Health Services located in Newark Delaware. Additionally there are 4 other sites that patients can access this medication from."

Answered by AI

Are there vacancies available in this research endeavor for participants?

"Affirmative. As per the information provided on clinicaltrials.gov, this medical study is currently in search of participants. The trial was initially published on January 2nd 2018 and was last modified November 1st 2022; 435 patients are needed from 4 distinct healthcare centres."

Answered by AI

What applications is RO6958688 typically employed for?

"RO6958688 is frequently prescribed for lymphoma, non-Hodgkin's as well as a range of other pathologies including recurrent cervical cancer, initial treatment and metastatic bladder cancer."

Answered by AI
~180 spots leftby Jun 2026